The FDA has approved a supplemental new drug application for Valtrex (valacyclovir HCI) manufactured by GlaxoSmithKline.
Treating Body Dysmorphic Disorder in Cosmetic Patients
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
Study Finds Successful Switching Strategy for Patients with Psoriasis After Suboptimal Response
The Cutaneous Connection: Using the Color Wheel to Discuss Nutrition
Establishing a Culture of Respect: Responding to Patient-Initiated Harassment
Advancements in Understanding the Skin's Microbiomes